Intellia Therapeutics (NTLA) PT Lowered to $14 at Guggenheim

Guggenheim analyst Debjit Chattopadhyay lowered the price target on Intellia Therapeutics (NASDAQ: NTLA) to $14.00 (from $45.00) while maintaining a Buy rating.

The analyst commented: 'Our BUY rating and updated $14/share PT (prior $45/share) are based on a 10-year risk-adjusted DCF analysis, applying a 12% discount rate and estimated fully diluted share count as of 2026. Our op-ex has been adjusted to reflect cash guidance from mgmt, which should be sufficient to fund operations into 2027. Following MAGNITUDE-2 and HAELO Ph 3 readouts, we model additional dilution in 2026 and 2027, reflected in our diluted share count. Since, both -2001 and -2002 are gene editors, available data are predictive of final outcomes hence, we assign an 80% POS for all clinical programs. We model -2002 peak sales of ~$330M (vs prior $380M). We model -2001 peak sales of ~ $700M (vs prior ~$1400M), which along with the pushout in launch for -2001 from 2028 to 2030, lowers our PT to $14."

You May Also Be Interested In

• Fiserv (FISV) PT Lowered to $60 at Freedom Broker
• Critical One Energy closes second tranche of flow-through placement
• AI/ML Innovations plans $2M private placement on the CSE